B2PRIME
10.6.2024 13:19:26 CEST | Business Wire | Press release
B2Prime, a leading global multi-asset and multi-market Prime of Prime liquidity provider, and Spotware, a premier and innovative trading platform provider, have announced a strategic partnership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610848632/en/
B2Prime, a Prime of Prime multi-asset liquidity provider, and cTrader, Spotware's flagship trading platform, have established a strategic partnership to expand trading opportunities. (Graphic: Business Wire)
The cTrader platform by Spotware is renowned for its advanced features that cater to professional traders:
Clear and stunning UI → Visually appealing and comprehensive user interface with a possibility for deep customisation.
Multi-asset trading without latency → A diverse range of supported asset classes alongside lightning-fast order entry and execution.
Depth of market (DOM) → Level II pricing empowers traders to evaluate market sentiment and anticipate potential price movements with higher accuracy.
Top availability → cTrader offers cross-platform accessibility with its Desktop, Mac, Web and Mobile (iOS and Android) apps.
Advanced risk management → cTrader users are equipped with sophisticated protection tools to trade with confidence.
Algo trading solutions → Out-of-the-box ecosystem for algo trading, with cBots, indicators and plugins.
Social trading platform → cTrader Copy is an integrated platform where strategy providers and investors meet.
Nicholas Chrysochos, Executive Director of B2Prime, remarks:
"Numerous hedge funds, money managers, professional traders, algorithmic traders, systematic traders, and high-net-worth individuals have shown a keen interest in accessing our extensive liquidity pool. In response to this growing demand, we have chosen cTrader as the platform through which these clients can access our bespoke liquidity products across a wide range of jurisdictions. We are licensed by CySEC, allowing us to serve the entire EU market, and we also hold licenses in Mauritius and Seychelles. This strategic growth is part of our commitment to helping our clients excel in competitive global markets."
Currently, B2Prime has several outstanding platforms, namely OneZero, PrimeXM, now cTrader, and FIX API connectivity.
Ilia Iarovitcyn, CEO of Spotware Systems, comments:
“We are excited to continuously develop our liquidity provision network, expand the asset offering and enhance the reliability of our trading environment. Partnering with B2Prime contributes to delivering competitive pricing and an exceptional trading experience to our end users. With our cutting-edge technology and B2Prime’s strategic growth, we are confident in driving innovation and success for our clients globally.”
The collaboration between B2Prime and Spotware extends B2Prime’s range of services and significantly enhances cTrader’s liquidity offering, making it even more competitive. With a portfolio of over 200 instruments across six asset classes—FOREX, Crypto CFDs, Spot Indices, Precious Metals, Commodities, and NDFs—B2Prime offers one of the most comprehensive liquidity solutions on the market.
The company guarantees access to the deepest liquidity pools sourced from the most reputable providers, ensuring competitive spreads and swift execution. Additionally, B2Prime provides multi-currency prime margin accounts and an institutional tiered-margin approach.
Spotware is a global technology provider, successfully delivering cutting-edge fintech solutions and infrastructure for over 14 years. The company has cultivated a sophisticated network of 240+ brokers and prop firms. With a user base exceeding 4 million traders, cTrader, Spotware’s flagship platform, stands out for its unparalleled innovativeness and user-friendly UI, setting new standards across the industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610848632/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom